OKYO Pharma announced that the first patient has been screened for its phase 2, multi-center, randomized, double-blinded, placebo-controlled trial, evaluating the efficacy and safety of OK-101 ophthalmic solution in subjects with dry eye disease, or DED.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on OKYO:
- OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2023) in San Diego, CA, May 5-8, 2023
- OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
- OKYO Pharma activates first OK-101 clinical trial site in the U.S.
- OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
- Notice of General Meeting and Publication of Circular